,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'mbc', 'bcsm', 'breast', 'destiny-breast04']
half of pts (55%) with mbc categorized as her2- actually do express low levels of her2, and in these pts trastuzumab deruxtecan provides pfs and os benefit -- results from phase 3 destiny-breast04 [#asco22 plenary lba3] . #bcsm 
Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.